Recherches "plusieurs pathologies" CHECK'UP Prospective Cohort Study to Identify the Predictive Factors of Response to PD-1 or PD-L1 Antagonists. Paris
Sein métastatique triple négatif CO40151 A phase ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel in patients with locally advanced or metastatic triple- negative breast cancer Paris
Mélanome uvéal et tumeurs oculaires IMCgp100-202 A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma Paris
Sein métastatique triple négatif IMPassion 132 (MO39193) A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer Paris
Pédiatrie Tumeurs cérébrales CDRB436G2201 Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) Paris ISABELLE AERTS
Sein Néoadjuvant ALIENOR Detection of Circulating Tumoral DNA Mutations (Sequential Assessment) Following Neoadjuvant Chemotherapy for Breast Cancer: Clinical Validity (ALIENOR Study) Paris, Saint-Cloud
Recherches "plusieurs pathologies" CIRCA-HPV (IC 2017-01) Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses. Paris, Saint-Cloud BRUNO BUECHER
Recherches "plusieurs pathologies" NIPINEC (GCO-001) A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) Paris NICOLAS GIRARD
Sein métastatique RH+ XENERA-1 (BI 1280-0022) A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease Paris
Recherches "plusieurs pathologies" CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Paris EMANUELA ROMANO